Daewoong Pharma (069620) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Daewoong Pharma stock KRW 125,648, price KRW 103,200, upside +21.8%, quality 50 out of 100. Rating: undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 91,039 KRW – 194,000 KRW · fair‑value band 98,929 KRW – 190,688 KRW · the 103,200 KRW price screens below the 125,648 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Daewoong Pharma in your weekly email
Every Wednesday you see whether Daewoong Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
Show moreShow less
It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins.
The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Stock analysis
Daewoong Pharma (069620) currently trades at 103,200 KRW, while our model-based Fair Value estimate is 125,648 KRW, implying the stock looks roughly 18% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 335,198 KRW per share, and 13 of the 16 models we run sit above the 103,200 KRW price.
Bear case: the Asset-Based group reads lowest at 37,183 KRW, and 3 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 98,929 KRW (bear) to 190,688 KRW (bull), the price of 103,200 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Daewoong Pharma reported revenue of 1.6T KRW in FY2025 versus 1.2T KRW in FY2021, a compound +8.0%/yr. Reported net income was 196B KRW in FY2025, compounding +67.9%/yr from FY2021.
Key figures
Market cap 1.2T KRW (≈ $871M) Small · P/E ratio 6.2 · P/S ratio 0.73 · EPS (TTM) 16,988 KRW · Dividend yield 0.6% · Net margin 12.0% · Return on equity 16.6% · Return on assets (EBIT) 7.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 22%, 069620 screens cheaper than that median.
Fair Value models
Bear98,929 KRWFair Value 125,648 KRWBull190,688 KRW
Price 103,200 KRW · Upside +21.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (14,009 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.47/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Start year 2020 (pandemic). Over 10 years: +6.5% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+71.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+70.4%
Dividend (yield on the price)0.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.51.5% vs 19.3%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 13%
2025 sits 346% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+21.8% · Above median
Profitability
Return on equity (12 months)16.6% · Top 25%
Return on assets8.3% · Top 25%
Net margin (12 months)12.0% · Above median
Operating margin (12 months)15.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)10.6% · Above median
Dividend yield (12 months)0.6% · Below median
Balance sheet
Debt / equity0.55× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Daewoong Pharma Fair Value". https://www.fairvalue-calculator.com/stock/069620
Frequently asked questions
Is Daewoong Pharma (069620) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 125,648 KRW versus a price of 103,200 KRW, about +22% upside (undervalued).
What is the fair value of 069620?
Our model-based fair value for Daewoong Pharma is 125,648 KRW (as of Nov 6, 2026), built from audited fundamentals. The current price: 103,200 KRW.
What is the quality score of 069620?
Daewoong Pharma has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daewoong Pharma (069620)?
Our model-based price target is the fair value of 125,648 KRW (as of Nov 6, 2026) from 16 valuation models. Cautious scenario 98,929 KRW, optimistic scenario 190,688 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daewoong Pharma stock forecast for 2026?
Our models put fair value at 125,648 KRW, about +22% upside versus a price of 103,200 KRW (undervalued). Cautious scenario 98,929 KRW, optimistic scenario 190,688 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daewoong Pharma (069620)?
Daewoong Pharma reported trailing-twelve-month revenue of about 1.6T KRW (latest available figure, as of Nov 6, 2026).
Does Daewoong Pharma pay a dividend?
Daewoong Pharma currently shows a dividend yield of 0.58% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Daewoong Pharma (069620) and when is the ex-dividend date?
Daewoong Pharma pays a dividend of 600.00 KRW per share a year, a dividend yield of 0.6%. The last ex-dividend date was Dec 29, 2025. The payout ratio is 3.5% of earnings. Our assessment: Token dividend. At a yield of 0.6% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.6% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Daewoong Pharma (069620)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daewoong Pharma it is 125,648 KRW per share (as of Nov 6, 2026), against a price of 103,200 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Daewoong Pharma stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 069620 trades below its calculated fair value: price 103,200 KRW, fair value 125,648 KRW, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 069620?
No. The price is what the market pays today (103,200 KRW); the fair value is what the company's own numbers justify (125,648 KRW). For Daewoong Pharma the two are 22,448 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daewoong Pharma worth?
The market values Daewoong Pharma at about 1.2T KRW (market capitalisation, as of Nov 6, 2026). Per share that is 103,200 KRW; our models calculate a fair value of 125,648 KRW per share.
What do the bullish and bearish scenarios say about 069620?
Our models span a range for Daewoong Pharma: cautious scenario 98,929 KRW, base 125,648 KRW, optimistic 190,688 KRW per share (as of Nov 6, 2026, price 103,200 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 069620?
Daewoong Pharma trades at a price-to-earnings ratio of 6.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 125,648 KRW is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 53.8. Other multiples: P/B 1.2, P/S 0.7, EV/EBITDA 6.1.
How solid is the balance sheet of Daewoong Pharma (069620)?
Balance-sheet figures for Daewoong Pharma (as of Nov 6, 2026): return on equity 16.6%, debt of 0.55 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 069620 from its 52-week high?
Daewoong Pharma trades at 103,200 KRW, about 47% below its 52-week high of 194,000 KRW and 4% above the low of 99,100 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 125,648 KRW is for.
Which stocks are comparable to Daewoong Pharma?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daewoong Pharma stock attractive at the current price?
The data as of Nov 6, 2026: price 103,200 KRW, calculated fair value 125,648 KRW (+22%), Quality Score 50/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 069620 calculated?
We run Daewoong Pharma through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 125,648 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Daewoong Pharma currently trades 18% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daewoong Pharma (069620)?
The closing price on Nov 6, 2026 was 103,200 KRW. Our model-based fair value is 125,648 KRW, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daewoong Pharma right now?
Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (98,929 KRW to 190,688 KRW) leaves room in how you read the outcome.
Key figures of Daewoong Pharma
How large is the market capitalisation of Daewoong Pharma (069620)?
The market capitalisation of Daewoong Pharma is 1.2T KRW (≈ $871M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daewoong Pharma (069620)?
The price-to-sales ratio of Daewoong Pharma is 0.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Daewoong Pharma (069620)?
Earnings per share at Daewoong Pharma are 16,988 KRW (price ÷ EPS = P/E 6.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daewoong Pharma (069620)?
The dividend yield of Daewoong Pharma is 0.6% (payout 3.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daewoong Pharma (069620)?
The net margin of Daewoong Pharma is 12.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daewoong Pharma (069620)?
The return on equity (ROE) of Daewoong Pharma is 16.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daewoong Pharma (069620)?
On an EBIT basis the return on assets of Daewoong Pharma is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daewoong Pharma (069620)?
The operating margin of Daewoong Pharma is 15.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daewoong Pharma (069620)?
Revenue at Daewoong Pharma is growing +10.6% versus a year earlier (3y avg +7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daewoong Pharma (069620)?
Earnings per share at Daewoong Pharma are growing −11.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Daewoong Pharma (069620) generate?
The free cash flow of Daewoong Pharma is −92.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Daewoong Pharma (069620) carry?
The net debt of Daewoong Pharma is 658B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daewoong Pharma in the live analysis
One click puts Daewoong Pharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026